Pharmaceutical Aspects of the Recombinant Human Serum Albumin Dimer: Structural Characteristics, Biological Properties, and Medical Applications
MetadataShow full item record
Human serum albumin is the most abundant protein in the blood. It is clinically used in the treatment of severe hypoalbuminemia and as a plasma expander. The use of albumins as a carrier for drugs is currently being developed, and some are now in the preclinical and clinical trial stages. The main technologies for utilizing an albumin as a drug carrier are protein fusion, polymerization and surface modification, and so on. Among these technologies, albumin dimerization has wide clinical applications as a plasma expander as well as a drug carrier. Despite the fact that many reports have appeared on drugs using an albumin dimer as a carrier, our knowledge of the characteristics of the albumin dimer itself is incomplete. In this review, we summarize the structural characteristics of recombinant albumin dimers produced by two methods, namely, chemical linkage with 1,6-bis(maleimido)hexane and genetically linked with an amino acid linker, and the physicochemical characteristics and biological properties of these preparations. Finally, the potential for pharmaceutical applications of albumin dimers in clinical situations is discussed.
Showing items related by title, author, creator and subject.
The potential of a cross-linked human serum albumin dimer in diabetic rats as an augmenting agent for antidiabetic drugsTaguchi, K.; Chuang, Victor; Yamasaki, K.; Kawai, K.; Maruyama, T.; Komatsu, T.; Otagiri, Masaki (2015)Purpose: The half-life of insulin analogs and glucagon like peptide-1 (GLP-1) receptor agonist is prolonged through binding to albumin, but this may not occur in hypoalbuminemic diabetic patients with protein leaking from ...
Ishima, Y.; Maruyama, T.; Otagiri, Masaki (2015)Human serum albumin has recently emerged as a versatile carrier for therapeutic agents against diabetes, cancer and infectious diseases. Market approved products include fatty acid derivatives of human insulin or the ...
Cross-linked human serum albumin dimer has the potential for use as a plasma-retaining agent for the fatty acid-conjugated antidiabetic drugsTaguchi, K.; Chuang, Victor; Yamasaki, K.; Urata, Y.; Tanaka, R.; Anraku, M.; Seo, H.; Kawai, K.; Maruyama, T.; Komatsu, T.; Otagiri, M. (2015)Objectives The half-life of fatty acid-conjugated antidiabetic drugs are prolonged through binding to albumin, but this may not occur in diabetic patients with nephropathy complicated with hypoalbuminemia. We previously ...